| GTO ID | GTC3489 |
| Trial ID | NCT05921162 |
| Disease | Retinitis Pigmentosa | Retinal Degeneration | Retinal Disease |
| Altered gene | MCO |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | vMCO-I|AAV2-MCO |
| Recruitment status | Recruiting |
| Title | A Long-Term Follow-Up Study in Subjects Who Received an Adeno-Associated Viral Vector Serotype 2 Containing the Multi-Characteristic Opsin Gene (vMCO-I) Administered Via Intravitreal Injection |
| Year | 2023 |
| Country | India |
| Company sponsor | Nanoscope Therapeutics Inc. |
| Other ID(s) | NTXMCO-005 |
| Vector information | |||||||||
|
|||||||||
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||